News

circle_logo2

CalciMedica Announces Positive Topline Data from Interim Analysis of Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia

Interim results showed Auxora plus standard of care improved time to recovery and reduced ventilator use in patients compared to standard of care alone  LA …

CalciMedica Raises $15 Million in Series C Financing Round Led by Valence Life Sciences

Funds to support ongoing clinical trials in patients with COVID-19 pneumonia and commercial manufacturing of Auxora™   LA JOLLA, Calif., May 22, 2020 – CalciMedica Inc. (“CalciMedica” …

CalciMedica Announces that FDA Has Strongly Recommended Moving to a Blinded Placebo-controlled Trial with Auxora™ in Patients with Severe COVID-19 Pneumonia

LA JOLLA, Calif., May 21, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment …

CalciMedica Announces Independent Safety Review Committee Recommendation to Continue Phase 2 Study of CM4620-IE in Patients with Severe COVID-19 Pneumonia on Low-Flow Oxygen Therapy

LA JOLLA, Calif., May 7, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment …

CalciMedica Expands Clinical Study to Assess CM4620-IE in Patients with Critical COVID-19 Pneumonia on High-Flow Oxygen Therapy

Phase 2 open-label study expands to additional sites across the U.S. and aims to enroll 120 patients  LA JOLLA, Calif., April 30, 2020 – CalciMedica Inc. …

Scroll to Top